Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma
1. Median PFS (5.6 months vs 5.6 months) and median OS (21.4 months vs 18.1 months) were similar in both...
Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma
1. The median progression-free survival in the metastasis-directed therapy arm was 10.3 months vs 2.5 months in the control arm...
Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy
1. When comparing corticosteroid peak dose for immunosuppression for anti–PD-1 plus anti–CTLA-4–related adverse events, the HR for OS was 1.66...
TKI With or Without SRS for Brain Metastases From EGFR/ALK Mutated NSCLC
1. Median overall survival was 41 months in the TKI-only group vs 40 months in the TKI-SRS group, with HR...
Multi-Organ Immune-related Adverse Events from Immune Checkpoint Inhibitors
1. Co-occurrences could be clustered together into 7 clusters based on the predominant organ system affected; endocrine, cutaneous, respiratory, gastrointestinal,...
Tisotumab Vedotin as Second or Third-Line Therapy for Recurrent Cervical Cancer
1. Median overall survival was 11.5 months in the tisotumab vedotin group and 9.5 months in the chemotherapy group, with...
Immunotherapy-Based Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer
1. The complete response rates (pathological and clinical) were similar (~55%) in both groups. 2. Grade 3-4 adverse events rates...
Amivantamab and Lazertinib in Untreated EGFR-Mutated Advanced NSCLC
1. The progression-free survival between the amivantamab–lazertinib group (23.7 months) and the osimertinib group (16.6 months) had an HR 0.70....
Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced NSCLC
1. Patients with no biochemical or radiographic evidence of progressive disease had a median treatment break of 20.3 months. 2....
Neoadjuvant Immunotherapy in Mismatch Repair–Deficient Colon Cancer
1. No disease recurrences were observed during the median follow-up time of 26.2 months. 2. Immune-related adverse events grade 3-4...